ROLE OF AT1, AT2 RECEPTOR AND Mas RECEPTOR ON OSTEOGENIC DIFFERENTIALIZATION OF CALVARIA OSTEOBLASTS FROM SPONTANEOUSLY HYPERTENSIVE RATS STIMULATED BY ANGIOTENSIN II.

• Grant number: 23/01096-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: April 01, 2023
• End date: December 31, 2023
• Field of knowledge: Biological Sciences - Pharmacology
• Principal Investigator: Sandra Helena Penha de Oliveira
• Grantee: Tayna Rodrigues Souza Cardoso
• Host Institution: Faculdade de Odontologia (FOA). Universidade Estadual Paulista (UNESP). Campus de Araçatuba. Araçatuba , SP, Brazil

Abstract

Arterial hypertension and osteoporosis represent multifactorial disorders, where genetic and environmental factors culminate in pathogenesis development. Recent studies suggest that angiotensin II, the main active peptide produced by the renin-angiotensin system (RAS), stimulates the differentiation and activity of osteoclasts, influencing bone metabolism and contributing to the imbalance between bone formation and reabsorption. Based on this principle, this work aims to evaluate the role of AT1, AT2, and Mas receptors on osteogenic differentiation induced by angiotensin II in cultures of osteoblasts from the calvaria of spontaneously hypertensive rats (CALV-SHR). For this, the calvaria of newborn rats will be extracted, and perforated and the pieces will be placed in small bottles for cell culture ("explant" method). Osteogenic differentiation will be induced by the addition of an osteogenic medium (OM). We will evaluate the parameters of cellular proliferation; total protein, alkaline phosphatase activity; and formation of a mineralized matrix of osteoblasts stimulated by angiotensin II (Ang II), in the presence of AT1, AT2, and Mas receptor antagonists. The evaluation of AT1, AT2, and Mas receptor expression in osteoblasts from primary cells of calvaria from spontaneously hypertensive rats will be evaluated by real-time RT-PCR. This study may bring new pharmacological tools for the control of osteoporosis in hypertensive patients.